Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle

Journal of Bone and Mineral Research

Volumn 19, Issue 5, 2004, Pages 722-727

  Morabito, Nunziata ^a,b   Gaudio, Agostino ^a   Lasco, Antonino ^a   Atteritano, Marco ^a   Pizzoleo, Maria Antonia ^a   Cincotta, Maria ^a   La Rosa, Mariangela ^a   Guarino, Roberta ^a   Meo, Anna ^a   Frisina, Nicola ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Palazzo Forte Gonzaga   (Italy)

Author keywords

Hypogonadism; Osteoporosis; Osteoprotegerin; RANKL; Thalassemia

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PYRIDINIUM DERIVATIVE; SEX HORMONE; AMINO ACID; BIOLOGICAL MARKER; CARRIER PROTEIN; CELL RECEPTOR; DEOXYPYRIDINOLINE; ESTRADIOL; GLYCOPROTEIN; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TESTOSTERONE; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMORAL ANGIOGRAPHY; HUMAN; LUMBAR SPINE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PROTEIN EXPRESSION; STEROID BLOOD LEVEL; THALASSEMIA; ADULT; BETA THALASSEMIA; BLOOD; CASE CONTROL STUDY; FEMALE; FEMUR; LUMBAR VERTEBRA; MALE; PATHOLOGY; RADIOGRAPHY; REGRESSION ANALYSIS; URINE;

ADULT; AMINO ACIDS; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CARRIER PROTEINS; CASE-CONTROL STUDIES; ESTRADIOL; FEMALE; FEMUR; GLYCOPROTEINS; HEMOGLOBINS; HUMANS; LUMBAR VERTEBRAE; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; TESTOSTERONE;

EID: 3242795997     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040113     Document Type: Article

References (45)

1. Ruggiero L, De Sanctis V 1998 Multicentre study on prevalence of fractures in transfusion-dependent thalassemic patients. J Pediatr Endocrinol Metab 11:773-778.
2. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N 2001 Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570-575.
3. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D 2001 Bone resorption is increased in young adults with thalassemia major. Br J Haematol 112:36-41.
4. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B 1998 High incidence of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 11:975-977.
5. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV 1998 Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 11:795-801.
6. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N 2002 Osteoporosis and beta-thalassemia major: Role of the IGF-I/IGFBP-III axis. Endocrinol Invest 25:338-344.
7. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P 1995 The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutic approaches. Clin Endocrinol (Oxf) 42:279-287.
8. Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM 1998 Bone mineral density in prepubertal children with beta-thalassemia: Correlation with growth and hormonal data. Metabolism 47:541-548.
9. de Vernejoul MC, Pointillart A, Golenzer CC, Morieux C, Bielakoff J, Modrowski D, Miravet L 1984 Effects of iron overload on bone remodeling in pigs. Am J Pathol 116:377-384.
10. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C 1996 Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 155:368-372.
11. Angastiniotis M, Pavlides N, Aristidou K, Kanakas A, Yerakaris M, Eracleous E, Posporis T 1998 Bone pain in thalassemia: Assessment of DEXA and MRI findings. Pediatr Endocrinol Metab 11:779-784.
12. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A 1998 Bone density and metabolism in thalassemia. J Pediatr Endocrinol Metab 11:785-790.
13. Riggs BL, Khosla S, Melton LJ III 1998 A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773.
14. Riggs BL 2000 The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203-1204.
15. Hofbauer LC, Khosla S 1999 Androgen effects on bone metabolism: Recent progress and controversies. Eur J Endocrinol 140:271-286.
16. Compston JE 2001 Sex steroids and bone. Physiol Rev 81:419-447.
17. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
18. Pacifici R 1996 Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043-1051.
19. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S 1999 The actions and interactions of sex steroids and growth factors/ cytokines on the skeleton. Mol Endocrinol 13:819-828.
20. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337.
21. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
22. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
23. Hofbauer LC, Heufelder AE 2000 Clinical review 114: Hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355-2363.
24. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527.
25. Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD 2000 Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 105:1833-1838.
26. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S 2002 Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347:175-184.
27. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R 2002 Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475.
28. Working Party of the General Haematology Task Force of the British Committee for Standards in Haematology 1998 The laboratory diagnosis of haemoglobinopathies. Br J Haematol 101:783-792.
29. Jung K, Lein M, Hosslin K, Grosse A, Roth S, Possinger K, Luftner D 2002 Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 17:177-181.
30. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A 2003 Soluble receptor activator of nuclear factor (kappa) B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 102:1064-1069.
31. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
33. Hofbauer LC, Hicok KC, Chen D, Khosla S 2002 Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 147:269-273.
34. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM 2002 Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550-1554.
35. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD 2001 Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162-3165.
36. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370.
37. Saika M, Inoue D, Kido S, Matsumoto T 2001 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142:2205-2212.
38. Aubin JE, Bonnelye E 2000 Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Medscape Womens Health 5:5.
39. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R 2001 Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836-8840.
40. Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, Szalay F 2002 Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 17:1961-1967.
41. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL 2002 Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399.
42. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360.
43. Browner WS, Lui LY, Cummings SR 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637.
44. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N 1997 Serum erythropoietin levels in patients with beta thalassemia major and intermedia. Pediatr Hematol Oncol 14:161-167.
45. Chen JS, Lin KH, Wang ST, Tsao CJ, Yeh TF 1998 Blunted serum erythropoietin response to anemia in patients polytransfused for beta-thalassemia major. J Pediatr Hematol Oncol 20:140-144.